Atrium Therapeutics Launches with $270 Million Focused on RNA Medicines for Genetic Heart Disorders Atrium Therapeutics, newly launched with $270 million, aims to advance RNA therapeutics designed for rare genetic cardiomyopathies. A transformative step for patients.

Atrium Therapeutics Launches with $270 Million Focused on RNA Medicines for Genetic Heart Disorders #USA #San_Diego #Cardiomyopathy #RNA_Medicines #Atrium_Therapeutics

Therna Biosciences Expands Leadership with Appointment of Devyn Smith and New Advisors Therna Biosciences strengthens its leadership team by appointing Devyn Smith, Ph.D., and expanding its advisory board, enhancing RNA medicine innovation.

Therna Biosciences Expands Leadership with Appointment of Devyn Smith and New Advisors #USA #San_Francisco #Devyn_Smith #RNA_Medicines #Therna_Biosciences

EQT Life Sciences Leads $39 Million Round for Aerska's RNA Therapeutics Innovation EQT Life Sciences has co-led a $39 million Series A financing round to enhance Aerska's technology delivering RNA medicines for neurological diseases, aiming to transform treatment options.

EQT Life Sciences Leads $39 Million Round for Aerska's RNA Therapeutics Innovation #USA #Amsterdam #EQT_Life_Sciences #RNA_Medicines #Aerska

EQT Life Sciences Invests $39 Million in Aerska's RNA Medicine Delivery Technology EQT Life Sciences co-leads a $39 million Series A funding for Aerska, which is developing advanced RNA medicines to treat neurological disorders.

EQT Life Sciences Invests $39 Million in Aerska's RNA Medicine Delivery Technology #Netherlands #Amsterdam #EQT_Life_Sciences #RNA_Medicines #Aerska

ARTHEx Biotech Engages Investors with Upcoming Industry Events Participation ARTHEx Biotech S.L. is set to engage with investors at key events focusing on innovative RNA medicine for rare diseases. Key executives will share insights.

ARTHEx Biotech Engages Investors with Upcoming Industry Events Participation #Spain #Myotonic_Dystrophy #Valencia #ARTHEx_Biotech #RNA_Medicines

ARTHEx Biotech Boosts Series B Round to $87M for Breakthrough RNA Medicine Development ARTHEx Biotech has successfully increased its Series B financing to $87 million, advancing the clinical development of its lead program ATX-01 for Myotonic Dystrophy Type 1.

ARTHEx Biotech Boosts Series B Round to $87M for Breakthrough RNA Medicine Development #Spain #Valencia #ARTHEx_Biotech #ATX-01 #RNA_Medicines